Articles > Shareholders of Zenas BioPharma, Inc. Encouraged to Take Action Before June 16, 2025 - ZBIO
- Levi & Korsinsky, LLP notifies Zenas BioPharma, Inc. investors of a class action securities lawsuit
- Faruqi & Faruqi, LLP reminds investors of a pending class action lawsuit deadline
- Pomerantz Law Firm alerts investors with losses on their investment in Zenas BioPharma, Inc. of an upcoming deadline
- Bronstein, Gewirtz & Grossman, LLC announces an opportunity for Zenas BioPharma, Inc. stockholders to lead a class action lawsuit
- Robbins Geller Rudman & Dowd LLP informs investors of the chance to lead an investor class action lawsuit
Zenas BioPharma, Inc. investors have until June 16, 2025, to seek guidance from Levi & Korsinsky, LLP regarding their rights in a class action securities lawsuit. The legal firm is reaching out to individuals who have suffered losses on their Zenas BioPharma, Inc. (NASDAQ: ZBIO) investment, urging them to take action before the deadline.
Investors who experienced losses exceeding $75,000 in Zenas are encouraged to contact Faruqi & Faruqi, LLP Securities Litigation Partner, James (Josh) Wilson directly. The firm is investigating potential claims against Zenas BioPharma, Inc. and is reminding investors of the upcoming deadline to seek the role of lead plaintiff in a federal securities class action against the Company.
Pomerantz Law Firm has also filed a class action lawsuit against Zenas BioPharma, Inc., advising investors with losses on their investments in the Company to get in touch. Investors can reach out to Danielle Peyton for more information on the legal proceedings and upcoming deadlines associated with the lawsuit.
Additionally, Bronstein, Gewirtz & Grossman, LLC has announced that Zenas BioPharma, Inc. stockholders have the opportunity to lead a class action lawsuit against the Company and certain officers. The lawsuit aims to recover damages for alleged violations of federal securities laws for those who purchased or acquired Zenas BioPharma securities during the initial public offering held on September 13, 2024.
Robbins Geller Rudman & Dowd LLP has informed investors of Zenas BioPharma, Inc. about the chance to lead an investor class action lawsuit. Investors who suffered losses due to securities fraud related to the Company’s initial public offering held in September 13, 2024, are urged to seek appointment as lead plaintiff before the June 16, 2025 deadline.
Zenas BioPharma, Inc. investors are advised to take prompt action and contact the relevant legal firms before the June 16, 2025 deadline to discuss their rights and potential recovery under federal securities laws. It is crucial for affected investors to explore their legal options and seek guidance in light of the pending class action securities lawsuit against the Company.
For more information:
Up/Down Rally Price Distribution Analyst Recommendations Earning Price Impact Analysis Seasonality
Shareholders of Zenas BioPharma, Inc. Encouraged to Take Action Before June 16, 2025 - ZBIO
By KlickAnalytics Data Insights | May 16, 2025 08:01PM ET
Key Points
- Levi & Korsinsky, LLP notifies Zenas BioPharma, Inc. investors of a class action securities lawsuit
- Faruqi & Faruqi, LLP reminds investors of a pending class action lawsuit deadline
- Pomerantz Law Firm alerts investors with losses on their investment in Zenas BioPharma, Inc. of an upcoming deadline
- Bronstein, Gewirtz & Grossman, LLC announces an opportunity for Zenas BioPharma, Inc. stockholders to lead a class action lawsuit
- Robbins Geller Rudman & Dowd LLP informs investors of the chance to lead an investor class action lawsuit
Zenas BioPharma, Inc. investors have until June 16, 2025, to seek guidance from Levi & Korsinsky, LLP regarding their rights in a class action securities lawsuit. The legal firm is reaching out to individuals who have suffered losses on their Zenas BioPharma, Inc. (NASDAQ: ZBIO) investment, urging them to take action before the deadline.
Investors who experienced losses exceeding $75,000 in Zenas are encouraged to contact Faruqi & Faruqi, LLP Securities Litigation Partner, James (Josh) Wilson directly. The firm is investigating potential claims against Zenas BioPharma, Inc. and is reminding investors of the upcoming deadline to seek the role of lead plaintiff in a federal securities class action against the Company.
Pomerantz Law Firm has also filed a class action lawsuit against Zenas BioPharma, Inc., advising investors with losses on their investments in the Company to get in touch. Investors can reach out to Danielle Peyton for more information on the legal proceedings and upcoming deadlines associated with the lawsuit.
Additionally, Bronstein, Gewirtz & Grossman, LLC has announced that Zenas BioPharma, Inc. stockholders have the opportunity to lead a class action lawsuit against the Company and certain officers. The lawsuit aims to recover damages for alleged violations of federal securities laws for those who purchased or acquired Zenas BioPharma securities during the initial public offering held on September 13, 2024.
Robbins Geller Rudman & Dowd LLP has informed investors of Zenas BioPharma, Inc. about the chance to lead an investor class action lawsuit. Investors who suffered losses due to securities fraud related to the Company’s initial public offering held in September 13, 2024, are urged to seek appointment as lead plaintiff before the June 16, 2025 deadline.
Zenas BioPharma, Inc. investors are advised to take prompt action and contact the relevant legal firms before the June 16, 2025 deadline to discuss their rights and potential recovery under federal securities laws. It is crucial for affected investors to explore their legal options and seek guidance in light of the pending class action securities lawsuit against the Company.
For more information:
Disclaimer: the above is a summary showing certain market information. KlickAnalytics is not responsible for any data errors, omissions or other information that may be displayed incorrectly as the data is derived from various resources and more. Communications displaying market prices, data and other information available in this post are meant for purely for informational purposes only and are not intended as an offer or solicitation for the purchase or sale of any security. Please do your own research when investing. All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit, or protect against loss in a down market.